Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASO-snoRNA
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ASO-snoRNA is an antisense oligonucleotide (ASO) therapy designed to target and reduce the levels of specific small nucleolar RNAs (snoRNAs) encoded within the introns of the *Rpl13a* gene, specifically U32a, U33, U34, and U35. These snoRNAs are known to elevate cellular levels of reactive oxygen species (ROS), which contribute to the progression of atherosclerosis. Developed by researchers at Duke University, ASO-snoRNA has demonstrated the ability to reduce atherosclerotic lesion area and circulating inflammatory markers (such as IL-1β) in preclinical mouse models (*Apoe-/-*). The therapy is administered via subcutaneous injection and aims to mitigate atherosclerosis in both early and late stages of the disease.
- Other names
- Rpl13a-snoRNA ASORpl-13a-snoRNA ASORpl 13a-snoRNA ASOantisense oligonucleotides targeting Rpl13a-snoRNAs
02
Targets
SNORD35A (Small nucleolar RNA, C/D box 35A)SNORD34 (Small nucleolar RNA, C/D box 34)SNORD33 (Small nucleolar RNA, C/D box 33)SNORD32A (Small nucleolar RNA, C/D box 32A)
Beyond the preview
Go deeper on ASO-snoRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASO-snoRNA.